Min S. Kang
Songnam, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models.
Journal: British journal of cancer
Published: June 01, 2025
Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer.
Journal: International journal of molecular sciences
Published: September 21, 2024
SOX5 inhibition overcomes PARP inhibitor resistance in BRCA-mutated breast and ovarian cancer.
Journal: Cell death & disease
Published: September 10, 2024
PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer.
Journal: International journal of molecular sciences
Published: November 16, 2023
Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer.
Journal: Cancers
Published: August 27, 2023
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: August 24, 2023
Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors.
Journal: Anticancer research
Published: October 25, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026